Although @entity14 ( @entity14 ) is a common cause of @entity5 , it is fortunately amenable to screening with faecal tests for occult blood and endoscopic tests. Despite the evidence for the efficacy of guaiac-based faecal occult blood tests (gFOBT), they have not been popular with primary care providers in many jurisdictions, in part because of poor sensitivity for advanced @entity14 (advanced @entity652 and @entity14 ). In order to address this issue, high sensitivity gFOBT have been recommended, however, these tests are limited by a reduction in specificity compared with the traditional gFOBT. Where colonoscopy is available, some providers have opted to recommend screening colonoscopy to their @entity1 instead of faecal testing, as they believe it to be a better test. Newer methods for detecting occult @entity1 blood in faeces have been developed. These tests, called @entity1062 ( @entity1062 ), are immunoassays specific for @entity1 haemoglobin. @entity1062 hold considerable promise over the traditional guaiac methods including improved analytical and clinical sensitivity for @entity14 , better detection of advanced @entity652 , and greater screenee participation. In addition, the quantitative @entity1062 are more flexible than gFOBT as a numerical result is reported, allowing customisation of the positivity threshold. When compared with endoscopy, @entity1062 are less sensitive for the detection of advanced @entity14 when only one time testing is applied to a screening population; however, this is offset by improved participation in a programme of annual or biennial screens and a better safety profile. This review will describe how gFOBT and @entity1062 work and will present the evidence that supports the use of @entity1062 over gFOBT, including the cost-effectiveness of @entity1062 relative to gFOBT. Finally, specific issues related to @entity1062 will be discussed, particularly with respect to organised @entity14 screening programmes.

Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and XXXX screening programme organisers need to know.

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer-related death'] @entity1062 :: ('MESH:D013736', 'Disease') :: ['FIT', 'faecal immunochemical tests', 'FIT implementation'] @entity14 :: ('MESH:D015179', 'Disease') :: ['CRC', 'colorectal neoplasms', 'colorectal cancer'] @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']
